TRVN
Trevena, Inc.
Set alert
0.01 USD 0.00 0.00%
0.012 Day range 0.012
0.0003 52-week range 0.066
- YTD
- -7.50%
- 1 year
- -7.50%
- Open
- 0.012
- Prev close
- 0.0111
- Mkt cap
- 9.59K
- Vol
- 210
- Avg vol
- 212
- EPS
- -290.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.012
- High
- 0.012
- Forward P/E
- -0.09
- Beta
- 0.00
- Short ratio
- 1.00
- Inst. own
- 10.50%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.32
- 200-d avg
- 8.10
- 1y target
- 100.00
Key statistics
- Market cap
- 1.60M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- -0.09
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -56.50
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 852.93K
- Short % of float
- 7.03%
- 50-day average
- 3.32
- 200-day average
- 8.10
Analyst view
Consensus: buy
Buy
Price target (mean) 100.00 +900800.9% upside
Now 0.0111
- Target (low)
- 75.00
- Target (mean)
- 100.00
- Target (high)
- 125.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -7.37.
Financials — quick view
TRVN Revenue — quarterly 325.00K
TRVN Net income — quarterly -4.89M
TRVN EPS — quarterly -5.75
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -5.79 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -9.25 | -5.75 | +3.50 | +37.84% |
| May 15, 2024 | Mar 1, 2024 | -9.25 | -9.00 | +0.25 | +2.70% |
| Apr 1, 2024 | Dec 1, 2023 | -13.00 | -26.50 | -13.50 | -103.85% |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -14.25 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -11.25 | -17.25 | -6.00 | -53.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | JMP Securities | reit | Market Outperform | Market Outperform |
| Mar 30, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Mar 30, 2023 | JMP Securities | reit | — | Market Outperform |
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trevena.com
News
- Trevena (NASDAQ:TRVN) Share Price Crosses Above 50-Day Moving Average – Here’s What Happened
- Critical Contrast: Ampio Pharmaceuticals (NYSE:AMPE) vs. Trevena (NASDAQ:TRVN)
- Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V; and bleuacacia ltd from The Nasdaq Stock Market
- Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
- Trevena Reports Third Quarter 2024 Results and Provides Business Update
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Trevena Announces Receipt of Nasdaq Delisting Notification
- Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
Your note
Sign in to keep a note on TRVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOURDOW CARRIE L | Chief Executive Officer | Stock Award(Grant) | Dec 13, 2023 | 642,923 |
| DEMITRACK MARK A | Officer | Stock Award(Grant) | Dec 13, 2023 | 306,224 |
| DRAKE PATRICIA M | Officer | Stock Award(Grant) | Dec 13, 2023 | 107,078 |
| SHIN BARRY | Chief Financial Officer | Stock Award(Grant) | Dec 13, 2023 | 308,821 |
| YODER ROBERT T. | Officer | Stock Award(Grant) | Dec 13, 2023 | 158,877 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.33% | 182,152 | 160.47K | Jun 29, 2023 |
| Blackrock Inc. | 0.82% | 112,173 | 98.82K | Jun 29, 2023 |
| Vanguard Group Inc | 0.53% | 72,812 | 64.15K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.48% | 65,167 | 57.41K | Jun 29, 2023 |
| Simplex Trading, LLC | 0.27% | 37,590 | 33.12K | Jun 29, 2023 |
| Captrust Financial Advisors | 0.24% | 33,076 | 29.14K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.51% | 70,176 | 61.83K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.24% | 33,095 | 37.73K | May 30, 2023 |
| Fidelity OTC Portfolio | 0.13% | 17,806 | 15.49K | Aug 30, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 8,946 | 10.20K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 7,457 | 8.50K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.05% | 7,358 | 8.39K | May 30, 2023 |